Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 5/20 | 0.32 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034763 | 0.95 | TSHR (0.43) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL13040233 | 0.92 | MEN1 (0.41) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL13034764 | 0.92 | MEN1 (0.41) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL7006602 | 0.92 | MEN1 (0.41) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL21242622 | 0.91 | CES2 (0.42) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL21242896 | 0.91 | CES2 (0.42) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL21242696 | 0.91 | CES2 (0.42) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL12641023 | 0.89 | MEN1 (0.41) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL19544555 | 0.89 | MEN1 (0.41) | TSHRRECQLCES2MEN1KMT2A | |
| SCHEMBL21440826 | 0.89 | MEN1 (0.41) | TSHRRECQLCES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| US-20220016215-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10435445-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | TSHR 57/4885RECQL 4569/4885CES2 4494/4885 |
| US-20220016215-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | TSHR 66/4885RECQL 3151/4885CES2 4794/4885 |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | TSHR 84/4885RECQL 2595/4885CES2 4566/4885 |
| US-11174301-B2 | Peptide compound | GIPR, GLP1R, GRPR | TSHR 57/4885RECQL 4569/4885CES2 4494/4885 |
| US-10435445-B2 | Peptide compound | GIPR, GLP1R, GRPR | TSHR 64/4885RECQL 4552/4885CES2 4534/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | TSHR 69/4885RECQL 3665/4885CES2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.